Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Breast and Gynecologic Cancer
M.D. Anderson Cancer Center
Completed ID
For more information, see NCT03063619
This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
Mammographically Dense Breast
Banu Arun, MD

See list of participating sites